Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Inclusion Criteria:

1. Age 18-65

2. Performance status of Eastern Cooperative Oncology Group (ECOG) grade 0 or 1

3. Tumor staged as American Joint Committee on Cance (AJCC) III-IV A (except T3-4 N0, T3N1), with newly histologically confirmed non-keratinizing NPC

4. Within 12-16weeks after completion of the recommended curative radiotherapy treatment

5. No clinical evidence of persistent loco-regional disease or distant metastases afterradiotherapy

6. Complete the recommended concurrent chemotherapy ± induction chemotherapy

7. Adequate hematologic (neutrophil count > 1.5×10^9/L, hemoglobin > 90g/L and plateletcount > 100×10^9/L), hepatic (alanine aminotransferase, aspartate aminotransferase ≤ 1.5×ULN, bilirubin ≤ 1.5×ULN, alkaline phosphatase < 2.5×ULN) and renal function (creatinine clearance > 50 ml/min)

8. Patients must be informed of the investigational nature of this study and give writteninformed consent.

Exclusion Criteria:

1. Patients who could not tolerate or allergic to capecitabine.

2. Illness that would interfere with oral medication, including dysphagia, chronicdiarrhea, or ileus

3. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, insitu cervical cancer.

4. Pregnancy or lactation (consider pregnancy test in women of child-bearing age andemphasize effective contraception during the treatment period).

5. Patients who received surgery treatment, biotherapy or immunotherapy during or beforeradiotherapy.

6. Patients who are receiving or highly likely to receive other chemotherapy treatment,biotherapy or immunotherapy.

7. History of previous radiotherapy before the curative radiotherapy (except fornon-melanomatous skin cancers outside intended RT treatment volume).

8. Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes before thecurative radiotherapy

9. Any severe intercurrent disease, which may bring unacceptable risk or affect thecompliance of the trial, for example, unstable cardiac disease requiring treatment,renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose > 1.5×ULN), and emotional disturbance.